Home › Open-Angle Glaucoma › NCT07816692

iDose TR Administration in an Office-Based Surgery Setting

Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion Criteria:

* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye
* Active ocular infection or inflammation
* History of hypersensitivity to travoprost or implant components
* Recent ocular surgery
* Uncontrolled systemic disease
* Any condition preventing safe implantation

About the study

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

What is being tested

• iDose TR (travoprost intracameral implant) 75 µg (combination product)

Sponsor: Glaukos Corporation · Participants: 30 · Started: May 13, 2026

Contact the study team

• Study Director · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT07816692

Locations in the U.S.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension
• Glaucoma

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.